GNE


Also found in: Financial, Wikipedia.
AcronymDefinition
GNEGenentech (former stock symbol, now DNA)
GNEGame Neverending (MMORPG)
GNEGross National Expenditure
GNEGateway Network Element (data communications)
GNEGlossop North End (UK soccer)
GNEGame Networking Engine
GNEGross Navigation Error (aviation)
GNEGenootschap Nederland-Engeland (Dutch: Netherlands-England Society)
GNEGraphical Network Editor (Nortel)
GNEGlobal Network Expert Communications Corporation
GNEGlobal Network Enterprise
GNEGeneral Network Error
References in periodicals archive ?
Joint administrator Nick Reed said: "While GNE has faced tough trading conditions in recent years, it will benefit from being part of a large, established company like Encore.
Aceneuramic acid prolonged release, also known as aceneuramic acid extended release (Ace-ER) outside of Europe, is being developed as a substrate replacement therapy for the treatment of adult patients with GNE Myopathy who have a genetic defect in sialic acid production, stated the company.
The idea that anyone might want shares in GNE Group is unlikely - it was dissolved in 2012.
The product is designed for the replacement of the deficient sialic acid substrate in patients with GNE Myopathy.
The joint venture, to be named GNE USA, will produce biodiesel oil using GNE's patented algae growing systems, which are designed to reduce costs of algae growing, while cutting expenses on oil extraction.
GNE service 4 will be diverted via A183, Mount Pleasant and Station Road in both directions, omitting Station Road between Shiney Row and Westerdale.
Aceneuramic acid extended release is aimed to replace the deficient sialic acid substrate in patients with GNE Myopathy also called Hereditary Inclusion Body Myopathy.
As would the fact that GNE Group plc no longer exists, so there's no reason why anyone would or could buy it shares.
Genie Energy (NYSE: GNE, GNEPRA), said today that the government of Israel has awarded its subsidiary, Genie Israel Oil and Gas, Ltd.
Ultragenyx Pharmaceutical, a biopharmaceutical company focused on product development for rare and ultra-rare diseases, has started its Phase III study of aceneuramic acid extended release earlier known as sialic acid-extended release tablets for the treatment of GNE Myopathy, it was reported on Friday.
NYSE: GNE, GNEPRA) announced that the expiration date for its pending exchange offer of up to 7,145,409 shares of Class B Common Stock for shares of Series 2012-A Preferred Stock on a one for one basis, has been extended to February 28, 2013 at 5:00 p.